FDA Looking Into Link Between Cholesterol Drug Vytorin, Cancer

August 22, 2008

The U.S. Food and Drug Administration (FDA) is conducting an investigation into a possible link between the cholesterol-lowering drug Vytorin, and various types of cancer....Washington (ChattahBox) – The U.S. Food and Drug Administration (FDA) is conducting an investigation into a possible link between the cholesterol-lowering drug Vytorin, and various types of cancer.

The FDA is investigating a report based on the trial called Simvastatin and Ezetimibe in Aortic Stenosis, or (SEAS).

From the report, they are trying their best to look at a possible linkn between Vytorin and the development of various cancers.

Vytorin is a cholesterol-lowering drugs, which has proven very effective in helping prevent cardiovascular problems by reducing bad cholesterol levels.

The drug is a combination of both drugs simvastatin and ezetimibe.

The FDA stated on Thursday that preliminary results from the SEAS trial have revealed that many who were treated with the drug, developed types of cancer.

The FDA is still trying to find a direct link between the two though, and has not told patients to stop using the drug.

Vytorin is manufactured by Merck & Co., and Schering-Plough Pharmaceuticals.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.